Calamos Advisors
IRWD icon

Calamos Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Calamos Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.1K Hold
14,520
– – ﹤0.01% 940
2026
Q1 		$51K Hold
14,520
– – ﹤0.01% 1148
2025
Q4 		$48.9K Buy
+14,520
New +$37.7K ﹤0.01% 876

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Calamos Advisors's IRWD Position: Q2 2026 in Review

Calamos Advisors held its Ironwood Pharmaceuticals (IRWD) position steady in Q2 2026 at 14,520 shares worth $61.1K. The position accounts for ﹤0.01% of the portfolio, ranked #940.

Calamos Advisors first reported a position in IRWD in Q4 2025 and has held it in 3 quarters since. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Calamos Advisors held 14,520 shares of Ironwood Pharmaceuticals worth $61.1K as of Q2 2026.
  • Calamos Advisors left its Ironwood Pharmaceuticals share count unchanged in Q2 2026.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Calamos Advisors's portfolio in Q2 2026, its #940 holding.
  • Calamos Advisors first reported a position in Ironwood Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.